Étiquette : psilocybine

BIBLIOGRAPHIE : Substances psychédéliques : anthropologie, sociologie, spiritualité, chamanisme, culture…, Docteur Christian Sueur, GRECC, mai 2020

BIBLIOGRAPHIE : Substances psychédéliques : anthropologie, sociologie, spiritualité, chamanisme, culture…   Docteur Christian Sueur, GRECC, mai 2020   Substances psychédéliques, anthropologie, sociologie, culture… : pp 1 - 6 Substances psychédéliques et Chamanisme : pp 7 - 10 Psychédéliques et “spiritualité” : religion, mysticisme, enthéogènes : pp 11 - 23  

Lire la suite

BIBLIOGRAPHIE : Substances psychédéliques : Généralités, Épistémologie, Pharmacologie, Neurophysiologie, Psychologie…, Dr Christian SUEUR, GRECC, mai 2020 (nouvelle version)

BIBLIOGRAPHIE : Substances psychédéliques : Généralités, Épistémologie, Pharmacologie, Neurophysiologie, Psychologie, … Dr Christian SUEUR, GRECC, mai 2020 (nouvelle version)   Substances psychédéliques : Généralités, Pharmacologie, Neurophysiologie : 1 - 17 Substances psychédéliques et «psychologie » : 18 - 20   Cf également : Bibliographie : Thérapies psychédéliques, Bibliographie : Substances psychédéliques, culture, chamanisme, spiritualité, religion… Bibliographie : Psilocybine, Bibliographie : LSD, Bibliographie : Ayahuasca, Bibliographie : Mescaline et Peyotl, Bibliographie : MDMA, Bibliographie : Tryptamines …

Lire la suite

Dynamic coupling of whole-brain neuronal and neurotransmitter systems, Morten L. Kringelbach et al., 2020

Dynamic coupling of whole-brain neuronal and neurotransmitter systems Morten L. Kringelbach, Josephine Cruzat, Joana Cabral, Gitte Moos Knudsen, Robin Carhart-Harris, Peter C. Whybrow Nikos K. Logothetis, and Gustavo Deco PNAS, 2020, 1-11 doi : 10.1073/pnas.1921475117   Remarkable progress has come from whole-brain models linking anatomy and function. Paradoxically, it is not clear how a neuronal dynamical system running in the fixed human anatomical connectome can give rise to the rich changes in the functional repertoire associated with human brain function, which is impossible to explain through long-term plasticity. Neuromodulation evolved to allow for such flexibility by dynamically updating the effectivity of the fixed anatomical connectivity. [...]

Lire la suite

De la première vague à la renaissance psychédélique, Dr Bertrand LEBEAU, ATHS 2019

De la première vague à la renaissance psychédélique ATHS 2019, Biarritz, 1-4 octobre 2019 Dr Bertrand LEBEAU LEIBOVICI     Les psychédéliques « classiques » A l’exception du LSD, ce sont des substances naturelles consommées par certains peuples depuis des millénaires Les psychédéliques « classiques » interagissent avec le récepteur 5HT2a : LSD psilocybine DMT (Diméthyltryptamine) mescaline Une définition plus large des psychédéliques : Les entactogènes et empathogènes: MDMA, MDA, 2-CB, 2C-T-7 etc. Les substances dissociatives antagonistes NMDA : kétamine, PCP Les substances dissociatives agonistes kappa-opioïdes : ibogaïne et Salvia Divinorum Tryptamines et phényléthylamines : Les psychédéliques sont : soit des tryptamines : LSD, psilocybine, DMT, ibogaïne, bufoténine (5-hydroxy-DMT) soit des phényléthylamines: MDMA, mescaline, MDA, 2C-B etc. La psychiatrie en [...]

Lire la suite

Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models, Claire J. Foldi et al., 2020

Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models Claire J. Foldi, Paul Liknaitzky, Martin Williams, Brian J. Oldfield Frontiers in Neuroscience, 2020 | Volume 14 | Article 43 : 1-8 doi : 10.3389/fnins.2020.00043   Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the potential for classical psychedelics, including psilocybin, to alleviate symptoms of AN [...]

Lire la suite

A Comparative Literature Survey of Psilocybin and LSD-25 Metabolism, Ian Joyce, 2017

A Comparative Literature Survey of Psilocybin and LSD-25 Metabolism Ian Joyce Capstone Project CHM 400 H Cal Poly Pomona, Winter 2017 | 1 - &ç   Psilocybin and lysergic acid diethylamide (LSD-25) are two of the most popular and well known psychedelic drugs. Although both of the compounds are currently illegal in the United States, a renewed interest has begun in recent years to examine and analyze these drugs for therapeutic use. This review analyzes the current research pertaining to the metabolism, biochemical pathways, receptor activity, biological signaling, physiological effects and the behavioral effects associated with both of these compounds. For psychedelic compounds to [...]

Lire la suite

Psychedelics for Mental Illness: The Evidence to Date, Todd Murphy, 2020

Psychedelics for Mental Illness: The Evidence to Date Todd Murphy Medscape, 12 March, 2020. https://www.medscape.com/viewarticle/926694_print Psychedelic drugs show real promise as treatment for psychiatric illnesses, particularly posttraumatic stress disorder (PTSD) as well as depression and anxiety, new research suggests. A literature review showed completed clinical trials support the efficacy of 3, 4-methylenedioxymethamphetamine (MDMA), commonly known by its street name of Ecstasy, to treat chronic PTSD. The review also confirmed that psilocybin, a compound contained in some species of mushrooms, significantly helped in the treatment of depression and cancer-related anxiety. Other promising, though more preliminary, results suggests that the hallucinogenic drug LSD (lysergic acid diethylamide) and a plant-based brew [...]

Lire la suite

Microdosing psychedelics : Motivations, subjective effects and harm reduction, Toby Lea et al., 2020

Microdosing psychedelics : Motivations, subjective effects and harm reduction Toby Lea, Nicole Amada, Henrik Jungaberl, Henrike Schecke, Michael Klein International Journal of Drug Policy, 2020, 75, 102600, 9 p. Doi : 10.1016/j.drugpo.2019.11.008 A B S T R A C T Background : In recent years there has been growing media attention on microdosing psychedelics (e.g., LSD, psilocybin). This refers to people routinely taking small doses of psychedelic substances to improve mental health and wellbeing, or to enhance cognitive performance. Research evidence is currently limited. This paper examines microdosing motivations, dosing practices, perceived short-term benefits, unwanted effects, and harm reduction practices. Methods : An international online survey [...]

Lire la suite

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders, Toby Lea et al., 2020

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders Toby Lea & Nicole Amada & Henrik Jungaberle & Henrike Schecke & Norbert Scherbaum & Michael Klein Psychopharmacology, 2020. Di : 10.1007/s00213-020-05477-0   Abstract Rationale : The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. Objectives : This paper examined subjective experiences of microdosing psychedelics to improve mental health or to cease [...]

Lire la suite

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic psychedelic Use : An Online Survey, Albert Garcia-Romeu et al., 2020

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic psychedelic Use : An Online Survey Albert Garcia-Romeu, Alan K. Davis, Earth Erowid, Fire Erowid, Roland R. Griffiths and Matthew W. Johnson Frontiers in Psychiatry, 2020, Vol 10, Article 955. Doi : 10.3389/fpsyt.2019.00955   Background : Observational data and preliminary studies suggest serotonin 2A agonist psychedelics may hold potential in treating a variety of substance use disorders (SUDs), including opioid use disorder (OUD). Aims : The study aim was to describe and analyze self-reported cases in which naturalistic psychedelic use was followed by cessation or reduction in other substance use. Methods : An anonymous online survey of [...]

Lire la suite